MapLight Therapeutics, Inc.
ML-009
autism spectrum disorder
Date
TBD
Phase 1 readout · Date TBD estimated
What's at stake
Phase 1 trial results for ML-009 in autism spectrum disorder are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 14h ago
“Complete IND-enabling studies in 2027”